EDGAR Filing Documents for 0001493152-22-036302

Form 8-K - Current report:

SEC Accession No. 0001493152-22-036302

Filing Date

2022-12-22

Accepted

2022-12-22 16:15:29

Documents

Period of Report

2022-12-21

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1		form8-k.htm iXBRL	8-K	51895
2		ex4-1.htm	EX-4.1	120425
3		ex10-1.htm	EX-10.1	299057
4		ex10-2.htm	EX-10.2	166716
5		ex10-3.htm	EX-10.3	114335
	Complete submission text file	0001493152-22-036302.txt		1083030

Data Files

Seq	Description	Document	Type	Size
6	XBRL SCHEMA FILE	qlgn-20221221.xsd	EX-101.SCH	3236
7	XBRL LABEL FILE	qlgn-20221221_lab.xml	EX-101.LAB	34240
8	XBRL PRESENTATION FILE	qlgn-20221221_pre.xml	EX-101.PRE	22365
10	EXTRACTED XBRL INSTANCE DOCUMENT	form8-k_htm.xml	XML	3497

Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011

Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165

Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)